Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of ...
1h
Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug ...
Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors$15 ...
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine. New Drug Application (NDA) Submission Expected in the ...
On January 22, 2025, the Lions Club of Penetanguishene presented a cheque for $5,200 to Victoria Evans, community Giving ...
Celebrities and wellness influencers are getting routine NAD+ infusions as an anti-aging hack, but are these expensives IV ...
GREENFIELD — Sue Ann Wortman Cancer Center is doubling the size of its infusion center, where patients receive chemotherapy ...
Baxalta spinoff was successful, Baxter's financial results fell substantially in 2022-23 on external pressures, such as inflation and weak medical utilization trends. With medical utilization rising, ...
Belfast Live on MSN10d
"My mother thought I was going to have a heart attack", Una Healy revealsUse precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Recent studies indicate that approximately 30 percent of urban Kenyan adults have elevated cholesterol levels, yet fewer than ...
A Nashville infusion therapy company has quietly opened a flurry of D.C.-area locations within the past few months — and intends to bring more to the market this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback